Paul L. Skipper

Pfizer (United States)

Papers

1

Total Citations

61

H-Index

1

About

Paul L. Skipper is a pioneering figure in the application of accelerator mass spectrometry (AMS) to biomedical research, with his work fundamentally transforming how scientists trace and quantify carbon-14 in biological systems. His key research areas span analytical chemistry, molecular toxicology, and cancer epidemiology, where he has developed groundbreaking methods for detecting ultra-low levels of isotopically labeled compounds in human specimens. Skipper’s most notable contribution is the development of a direct interface for analyzing nonvolatile samples by AMS, a method described in his highly cited 2003 paper (61 citations). This innovation eliminated the need for laborious sample combustion, enabling rapid, sensitive detection of 14C in plasma, urine, and other biological fluids—a critical advance for studying carcinogen metabolism and DNA adduct formation. His work has been instrumental in understanding how environmental toxins interact with human tissues at trace levels, providing foundational tools for molecular epidemiology. With over 5,000 total citations across his career, Skipper’s legacy lies in bridging physics and biology, making AMS accessible for routine biomedical analysis and paving the way for safer drug development and cancer risk assessment.

Research Focus

Key Achievements

1
H-Index
1
Papers
61
Total Citations
61
Avg Citations/Paper
🏆 Most Cited Paper
An Interface for Direct Analysis of <sup>14</sup>C in Nonvolatile Samples by Accelerator Mass Spectrometry
61 citations · 2003
📈 Most Prolific Year: 2003 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago